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Abstract
Background: Macrophages provide an interface between innate and adaptive immunity and are important long-lived
reservoirs for Human Immunodeficiency Virus Type-1 (HIV-1). Multiple genetic networks involved in regulating signal
transduction cascades and immune responses in macrophages are coordinately modulated by HIV-1 infection.
Methodology/Principal Findings: To evaluate complex interrelated processes and to assemble an integrated view of
activated signaling networks, a systems biology strategy was applied to genomic and proteomic responses by primary
human macrophages over the course of HIV-1 infection. Macrophage responses, including cell cycle, calcium, apoptosis,
mitogen-activated protein kinases (MAPK), and cytokines/chemokines, to HIV-1 were temporally regulated, in the absence
of cell proliferation. In contrast, Toll-like receptor (TLR) pathways remained unaltered by HIV-1, although TLRs 3, 4, 7, and 8
were expressed and responded to ligand stimulation in macrophages. HIV-1 failed to activate phosphorylation of IRAK-1 or
IRF-3, modulate intracellular protein levels of Mx1, an interferon-stimulated gene, or stimulate secretion of TNF, IL-1b, or IL-
6. Activation of pathways other than TLR was inadequate to stimulate, via cross-talk mechanisms through molecular hubs,
the production of proinflammatory cytokines typical of a TLR response. HIV-1 sensitized macrophage responses to TLR
ligands, and the magnitude of viral priming was related to virus replication.
Conclusions/Significance: HIV-1 induced a primed, proinflammatory state, M1HIV, which increased the responsiveness of
macrophages to TLR ligands. HIV-1 might passively evade pattern recognition, actively inhibit or suppress recognition and
signaling, or require dynamic interactions between macrophages and other cells, such as lymphocytes or endothelial cells.
HIV-1 evasion of TLR recognition and simultaneous priming of macrophages may represent a strategy for viral survival,
contribute to immune pathogenesis, and provide important targets for therapeutic approaches.
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Introduction
Tissue macrophages play a central role in immune response
pathways and are major targets for chronic infection by viruses
including HIV-1. Infected macrophages constitute a stable viral
reservoir that facilitate spread of HIV-1 to other cells or tissue
compartments and contribute to immune pathogenesis [1–7].
HIV-1 interacts through multiple signaling pathways to repro-
gram the transcriptome and the proteome of host cells [5,8–13].
HIV-1-induced stimulation of macrophages is a multi-step process
that occursdirectly ininfected cells,aswell asindirectlyinbystander
cellsthroughparacrinesignaling.Forexample,interactionsbetween
Env gp120 and the cellular CD4/coreceptor complexes initiate
response cascades through intracellular phosphorylation within the
MAPK pathway leading to production of tumor necrosis factor
(TNF) [10,14]. While Env gp120 activates multiple signaling
pathways, including G-protein coupled receptors (GPCR) [15],
protein tyrosine kinase 2 (PYK2) [9,16], calcium [9,11], or signal
transducer and activator of transcription (STAT) factors [12], other
viral proteins also mediate effects on macrophage gene expression.
The accessory protein Nef interacts with and inhibits the function of
the cellular proapoptotic protein, ASK1 [17]. In addition, HIV-1
genomic RNA activates plasmacytoid dendritic cells (pDC) and
monocytes through pattern recognition receptors, specifically Toll-
like receptor-7 (TLR7), which initiate a signal transduction cascade
to mediate release of TNF and interferons [18,19] that may
contribute to viral replication [20].
Coordinate induction of multiple pathways can lead to cross-
talk through convergence of signals at the level of phosphorylation
and/or other post-translational modifications resulting in complex
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of signals is mediated by molecular hubs that include biochem-
ically diverse proteins, such as transcription factors (i.e. NF-kB),
kinases (i.e. NEMO or PRKCG), or structural proteins (i.e.
YWHAE) [21–25]. Molecular hubs integrate pathways into
complex networks, regulate the overall organization of signaling
networks, amplify or inhibit signals, and increase the complexity of
the transcriptional response machinery [26,27]. Network interac-
tions can be mapped by using systems biology strategies that, in
contrast to a single pathway approach, integrate multifaceted
analyses to provide a global and dynamic perspective of cellular
responses [28,29].
Macrophage activation is classically defined as M1 (pro-
inflammatory) or M2 (regulatory) [30]. Classical macrophage
activation involves two steps, priming (e.g. IFN-c treatment) and
triggering (e.g. LPS treatment), which modulate gene or protein
expression [31,32]. In the present study, we used a systems biology
approach to integrate genomic and proteomic data across
signaling networks with a focus on calcium, apoptosis, and MAPK
known from independent pathway studies to respond to viral
proteins and contribute to HIV-1 infection [9,33,34]. Pathway
analysis also incorporated cell cycle and TLR pathways to
characterize global and comprehensive host cell response and to
define the activation phenotype of macrophages in response to
replicating virus.
Results
HIV-1 treatment of macrophages stimulates a temporal
program of gene expression
Following HIV-1 treatment of macrophages, a subset of 939 probe
sets, representing 860 genes that displayed at least 5-fold altered gene
expression relative to mock cultures, was analyzed by hierarchical
agglomerative clustering (Fig. 1A). Probe sets were distributed into
nine major clusters, based on similar patterns of signal intensity
values, with about 70% distributed among six clusters. Median
temporal change in signal intensity within each of the six clusters was
represented graphically as waveforms that fell into two general
patterns (Fig. 1B). Relatively higher steady state levels occurred early
by day 2 for a majority of the probe sets in clusters B, C, D, and G,
while response was delayed in Clusters E and I (Fig. 1B). Overall a
majority of genes and proteins were increased in steady-state levels in
response to virus. Temporal transcriptome profiles revealed the
magnitude, as well as the dynamic nature of macrophage gene
expression stimulated by HIV-1 treatment.
The probe sets included genes that were distributed among 67
pathways (data not shown).Altered expression of genes and proteins
were organized into the framework of functional pathways. To
analyze the pathway networks that reflect classical activation, we
focused on five pathways, includingcalcium,apoptosis,andMAPK,
that responded to virus with statistical significance in Pathway
Express (P=1.3610
23, 1.4610
22, or 6.6610
25, respectively), as
well as cell proliferation and TLR, that apparently failed to respond
to virus (P=0.69 or 0.23, respectively).
Calcium signaling pathway impacted by virus
Calcium signaling is a hallmark of host cell activation and an
immediate response to viral recognition [35]. HIV-1 is known to
mobilize calcium release from both intracellular and extracellular
reservoirs leading to apoptosis and MAPK signaling pathways
through molecular hubs [36–38]. Collective analyses of our data
identified multiple cellular factors comprising calcium-dependent
signaling cascades, including the molecular hubs PRKCG (Entrez
Gene ID: 5582) and NF-kB (Entrez Gene ID: 4791) (Fig. 2A).
Virus treatment detectably altered 33 (,15%) of the 266 probe
sets associated with calcium signaling. While probe sets were
distributed among at least five different expression clusters (A, B,
C, D, G, and H), most displayed increased gene expression by day
2 of virus treatment (Fig. 2B).
Dynamic modulation of apoptotic signaling pathways in
HIV-1-treated macrophages
The apoptosis signaling pathway is composed of two opposing
arms, antiapoptosis and pro-apoptosis (Fig. 3A). In contrast to
lymphocytes, macrophages exposed to HIV-1 are relatively
resistant to apoptosis [39,40], which led us to expect that
macrophages would display an anti-apoptotic transcriptome and
proteome response to virus. Surprisingly, within 2 days, when the
greatest response to virus occurred, multiple pro-apoptotic factors,
including BID (Swiss-Prot ID: P55957), PAK2 (Entrez Gene ID:
5062), and ASK1 (Entrez Gene ID: 4217), displayed increased
expression, while anti-apoptotic factors, such as BCL2 (Entrez
Gene ID: 596), were decreased in expression (Fig. 3B). Although
Figure 1. Temporal program of gene expression modulated in
HIV-1-treated macrophages. (A) Gene expression values from HIV-
1-treated macrophage cultures were divided by expression values from
mock-treated cultures to derive fold-change ratios. Median values were
calculated for all four donors and hierarchical agglomerative clustering
with absolute correlation (un-centered) of approximately 900 genes was
based on expression patterns over time. Median increase (red) or
decrease (green) of expression ranged between +4 and 24 for each
gene. Genes were distributed into nine cluster patterns designated A-I
(color coded on right Y axis of the dendrogram) Major branches in the
dendrogram were defined by correlation coefficients of greater than
0.75 (mean 0.85, range 0.75 to 0.96). (B) Six cluster patterns were
selected for further analysis based on their unique temporal expression
patterns. Two patterns of temporal gene expression were observed:
early day 2 (clusters B, C, D, and G), and late day 7 (clusters E and I).
doi:10.1371/journal.pone.0003664.g001
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increased in response to virus, both are molecular hubs that serve
as signaling partners in other pathways, including MAPK and
TLRs. Over the course of viral replication, relative expression of
pro-apoptotic genes declined and anti-apoptotic genes increased
(Fig. 3C). The transcriptome response was extended by analysis of
the intracellular proteome compartment that also displayed
increased levels of pro-apoptotic proteins, such as BAD (Swiss-
Prot ID: Q92934), APAF-1 (Swiss-Prot ID: O14727), and
Caspase-7 (Swiss-Prot ID: P55210), within 2 days of viral
treatment, while anti-apoptotic proteins, such as CDC42GAP
(Swiss-Prot ID: Q07960), showed lower expression levels on day 2
compared to mock (Fig. 3D). Results indicate the dynamic
temporal response by macrophages to HIV-1.
Figure 2. HIV-1 directed effects on calcium release pathways. (A) Model of calcium signaling pathway altered in macrophages by 2 days of
HIV-1 treatment. Factors increased in expression by HIV-1 treatment are red and factors expressed at lower levels by virus are green. Ovals represent
factors detected at the RNA level and hexagons are factors detected at both the RNA and protein level. Molecular signaling hubs are depicted with a
yellow border. (B) Heat map displaying temporal expression of genes whose protein products are involved in calcium signaling over 7 days of HIV-1
treatment relative to mock. The heat map includes Entrez Gene identification number and expression cluster corresponding to the gene. Red
indicates expression levels above the mean, black are equal to the mean, and green represents values below the level of the mean.
doi:10.1371/journal.pone.0003664.g002
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MAPK activation is triggered in response to soluble Env gp120
engagement with surface receptor complex and is required for
efficient production of infectious viral particles in primary T-
lymphocytes and monocyte/macrophages [41–43]. In our studies,
virus treatment of macrophages had a global effect on MAPK
signaling that extended from cell-surface receptors to transcription
factors (Fig. 4A). From a global perspective, HIV-1 had an overall
inductive effect on the relative steady state levels of mRNA and
proteins involved in the MAPK signaling cascade in macrophages
(Fig. 4B and 4C).
Virus alters macrophage molecular program
independent of cell proliferation
Calcium, apoptosis, and MAPK pathways interface through
molecular hubs, such as NF-kB, NEMO, PRKCG, JNK (Swiss-
Prot ID: P45983), and YWHAE (Swiss-Prot ID: P62258), with
multiple signaling pathways, including cell proliferation and TLR.
Yet, in contrast to calcium, apoptosis, and MAPK pathways,
neither cell proliferation nor TLR pathways was identified as
significantly altered by Pathway-Express analysis.
Although HIV-1 is capable of crossing the nuclear envelope of
terminally differentiated cells without a requirement for prolifera-
tion [44,45], some groups report a portion of macrophages
proliferating in vitro and have an enhanced susceptibility to HIV-1
infection [46,47]. In contrast, other groups find that HIV-1
treatment increases the expression of CDK inhibitors, specifically
CDKN1A (also known as p21
Cip1/WAF1, Swiss-Prot ID: P38936),
and other targets in the cell cycle important for efficient viral
replication [13,48]. To determine if HIV-1 interactions with
macrophages are accompanied by macrophage proliferation in
our studies, two approaches were used. HIV-1- or mock-treated
macrophages labeled with propidium iodide showed no differences
in DNA content over 10 days (data not shown). A more sensitive
assessment of proliferation involved labeling cellular proteins with
the fluorescent molecule, CFSE [49]. When CFSE-labeled
macrophages were cultured for 7 days in the presence or absence
of HIV-1 no change in fluorescent intensity was detected (Fig.5A–
B). Other treatments, such as IL-3 and GM-CSF, also failed to
induce proliferation of macrophages (data not shown). For
comparison, cellular proliferation in PBMC was evaluated. A single
peakof fluorescence in unstimulatedPBMC after 4 days indicated a
quiescent population of cells (Fig. 5C), while PHA stimulation
produced six discrete populations with fluorescence intensities less
than that of unstimulated PBMC reflecting cell proliferation among
more than 96% of PBMC (Fig. 5D). Taken together, results
demonstrate that virus-related modulation of the macrophage
transcriptome and proteome was independent of proliferation.
Coordinate stimulation of macrophage transcriptome is
independent of TLR signaling
Activation across calcium, apoptosis, and MAPK pathways
converge on NF-kB, a transcription factor that functions as a
molecular hub (Fig. 6). Yet, not all pathways leading to or
interfacing with NF-kB responded to virus in our studies. A
striking example was the TLR pathway that displayed essentially
no response over the course of viral replication. Although proteins,
particularly phosphoproteins, in the TLR pathway were under-
represented in the PowerBlot analysis, transcriptome analysis
included 27 members of the TLR signaling pathways (Fig. 7). Only
five displayed increased expression. Increased expression of IRF-3
(Enrez Gene ID: 3661) was detected in only one of three
macrophage donors, while NF-kB, NEMO, MAP2K5 (Swiss-Prot
ID: Q13163), and p38 (Swiss-Prot ID: Q16539) function as
molecular hubs in multiple signaling pathways and are not
restricted to TLR pathways.
HIV-1 escapes TLR response
TLR signaling is transmitted through a MyD88-dependent
and/or, depending on the TLR, a MyD88-independent pathway
(Fig. 7). Both pathways result in production of proinflammatory
cytokines, such as type I interferons and TNF (Swiss-Prot ID:
P01375) [50]. To determine if proximal signaling molecules
respond to virus, we evaluated phosphorylation of TLR signaling
members, IRAK-1 (specific for the MyD88-dependent pathway,
Swiss-Prot ID: P51617) and IRF-3 (member of both pathways).
Treatment of macrophages with TLR agonists LPS (primarily
TLR4 agonist) or Poly(I:C) (primarily TLR3 agonist) produced
phosphorylated forms of IRAK-1 within 30 minutes or IRF-3
within one hour (Fig. 8A–F). Phophorylated forms of IRAK-1 or
IRF-3 appeared transiently and decreased by 3 hours. Steady-state
levels of total IRF-3 protein remained relatively stable over the
course of treatment, while diminished levels of IRAK-1 following
LPS treatment failed to recover after 24 hours (Fig. 8B) or
48 hours (data not shown). In contrast to other ligands, HIV-1
treatment of macrophages produced a transient increase in IRAK-
1, but no phosphorylation of either IRAK1 or IRF3 (Fig. 8G–I).
The relatively limited proportion of macrophages infected by
HIV-1 within the first 24 hours could limit detection by western
blot of phosphorylated/activated IRAK-1 or IRF3. To address
this issue, levels of Mx1 protein (Swiss-Prot ID: P20591) were
measured. Mx1 (Swiss-Prot ID: P20591), an antiviral interferon-
stimulated gene, is a relatively stable, sensitive marker for low
levels of interferon and innate immune activation [51]. Although
treatment of macrophages through multiple TLRs 4, 3, or 8 for
24 hours stimulated increased intracellular levels of the Mx1
protein, treatment by HIV-1 induced no expression of Mx1
protein (Fig. 9). Although macrophages recognize and respond to
TLR agonists via MyD88-dependent or independent pathways,
HIV-1 has no apparent impact on targets downstream in TLR
signaling through either pathway. HIV-1 interactions with
macrophages were insufficient to trigger proinflammatory cytokine
responses indicative of classical activation.
HIV-1 primes macrophages for enhanced response to TLR
agonists
Stimulation of macrophages through TLR signaling rendered
cells refractory to HIV-1 infection (data not shown) [52–55].
Figure 3. HIV-1 treatment affects expression patterns of members of the apoptotic pathway in primary macrophages. (A) Diagram of
the apoptotic signaling pathway depicting factors altered in expression within macrophages upon treatment with HIV-1 within 2 days. Factors
increased in expression by HIV-1 treatment are red and factors expressed at lower levels by virus are green. Ovals represent factors altered at the RNA
level and diamonds are factors modulated at the protein level. Signaling hubs are depicted with a yellow border. The orange pentagon represents
virus-encoded Nef. (B) Heat map representing expression of genes whose protein products are involved in apoptosis. The heat map includes the
Entrez Gene identification number and the expression cluster that the gene belongs to. Red indicates expression profiles above the mean, black are
equal to the mean, and green represents values below the level of the mean. (C) Median Log2 differences of pro-apoptotic genes (blue) and anti-
apoptotic genes (orange) in the HIV-treated samples versus mock plotted over 7 days. (D) PowerBlot of apoptotic proteins altered in macrophages
by HIV-1 treatment. The signal intensity ratio of HIV-treated to mock-treated is indicated for each protein above the blot.
doi:10.1371/journal.pone.0003664.g003
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PLoS ONE | www.plosone.org 5 December 2008 | Volume 3 | Issue 12 | e3664Figure 4. Factors of MAPK pathway altered in expression by HIV-1. (A) Diagram describing MAPK pathway including altered genes and
proteins following 2 days HIV-1 treatment. Factors increased in expression by HIV-1 treatment are red and factors expressed at lower levels by virus
are green. Ovals represent factors altered at the RNA level, diamonds are factors modulated at the protein level, and hexagons are factors altered at
both RNA and protein levels. Signaling hubs are depicted with a yellow border. (B) Expression profiles of genes involved in MAPK signaling and
altered by virus treatment over 7 days are displayed in a heat map. Heat map includes Entrez Gene identification number and the expression cluster
that the gene belongs to. Red indicates expression profiles above the mean, black equal to the mean, and green represents values below the level of
the mean. (C) PowerBlot of MAPK proteins altered in macrophages by HIV-1 treatment. The signal intensity ratio of HIV-treated to mock-treated for
each protein is indicated above the blot.
doi:10.1371/journal.pone.0003664.g004
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initial step in classical activation, a spreading viral infection was
established that produced a three log increase in supernatant p24
over 10 days (Fig. 10, inset). On days 2, 5, and 10 post infection,
macrophages were stimulated for 24 hours with ligands for TLR 4
(LPS), 3 (Poly(I:C)), and 8 (CL075). Enhanced TNF levels were
observed as early as 2 days and increased over time to a maximum
between days 5 and 10, paralleling viral infection (Fig. 10).
To examine the breadth of the priming response, additional
TLR ligands and proinflammatory cytokines, which are amplified
as a consequence of innate immune activation, were analyzed at
the time of maximum response, day 10. Macrophages were treated
for 24 hours with any one of a variety of TLR ligands, including
LPS, Poly(I:C), and CL097 (TLR7/8 agonist), as well as CL075
(TLR8 agonist) or R837 (TLR7 agonist) to distinguish differences
that might result from selective activation through individual
TLRs. Overall, each agonist stimulated production of TNF, IL-1b
(Swiss-Prot ID: P01584), and IL-6 (Swiss Prot ID: P05231)
(Fig. 11A–C, gray bars). In contrast, no proinflammatory cytokines
were detected with HIV-1 treatment alone. Yet, when HIV-1
infected macrophage cultures were treated with TLR agonists,
increased levels of cytokines were produced (Fig. 11A–C, black
bars). HIV-1 infection of macrophages increased LPS response by
about 3- to 5-fold, while response to other TLR ligands was
increased by a factor of 10 or greater. Results indicate that HIV-1
can provide an effective priming signal to macrophages, which
sensitizes the cells to TLR agonists and enhances proinflammatory
cytokine responses.
Discussion
HIV-1 stimulates dynamic and complex responses within
macrophages through alteration of expression or modification of
cellular genes or proteins. While virus modulates multiple signaling
pathways over the course of infection, HIV-1 has a selective,
rather than global, impact on macrophages. Our analysis
Figure 5. Macrophage activation by virus is independent of cell proliferation. Macrophage cellular proliferation over 10 days (A) in the
absence or (B) presence of HIV-1. Cellular proliferation of PBMC in 4 days (C) in the absence of stimulation or (D) the presence of PHA.
doi:10.1371/journal.pone.0003664.g005
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establish spatial-temporal relationships across signaling pathways
that organize virus-specific activation programs into an HIV-1
response phenotype for macrophages.
Pathway analysis provides a rational and unsupervised statistical
algorithm for integrating large transcriptome and proteome data
sets and quantifying viral impact on the pathways. High-
throughput transcriptome discovery across multiple pathways
enhanced by proteomic approaches reduces the significance of
outlier data points, such as increased IRF-3 gene expression by
HIV-1 in a single donor, which may be difficult to interpret on an
individual pathway basis by a single method. Our study was
designed to discern physiological responses in a population of
macrophages exposed to virus, rather than to distinguish between
the direct and indirect effects of virus on cells. Yet, even though
only a minority of macrophages was infected by HIV-1 within
2 days, the initial round(s) of virus replication produced the
greatest differences in gene expression raising the possibility that
the macrophage response to HIV-1 involved bystander cells.
Viral impact on signaling is frequently studied by investigating
discrete pathways in cells treated with an isolated viral component,
for example Env gp120 [9,11,56], Tat [57,58], Nef [34,59], Vpr
[60], or synthetic RNA corresponding to subgenomic regions of
HIV-1 [18]. While these studies have provided a framework for
network analysis, our global strategy builds insight through the use
of whole virus replication to assess the coordinate impact on
multiple cell signaling pathways by viral gene expression during
spreading infection. Several pathways in macrophages, including
calcium, MAPK, and apoptosis, which are impacted by individual
viral components, were also modulated at the level of gene and
protein expression over the course of viral replication. In contrast,
Env gp120 treatment of macrophages induces the production of
TNF [10], while our studies, unexpectedly, failed to detect TNF
secretion in response to HIV-1, which could reflect differences in
signaling between monomeric Env gp120 and virion-associated
trimeric Env complexes, quantitative difference between envelope
glycoproteins in soluble or virion form, or activity by viral proteins
post-entry to suppress signaling. The fact that multiple signaling
pathways can result in similar cytokine responses argues that a
global analysis of all pathways simultaneously is important in
interpreting cellular response.
Changes in macrophage cell cycle or pathways can be critical
for productive HIV-1 infection [13,48]. Our studies demonstrate
that changes in cell proliferation pathways by virus are
independent of DNA doubling or cell proliferation. Therefore,
transitions within compartments of G1, prior to DNA replication
Figure 6. Summary of signaling pathways altered or evaded by virus. Factors expressed at higher levels in HIV-treated than mock are red
and factors expressed at lower levels in HIV-treated than mock are green. Ovals represent factors detected at the RNA level, diamonds are factors
detected at the protein level, and hexagons are factors detected at both RNA and protein. Signaling hubs are depicted with a yellow border.
doi:10.1371/journal.pone.0003664.g006
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intracellular milieu for viral infection [47,61]. Alternatively, cell
cycle factors may be essential for HIV-1 replication in macro-
phages independent of their role in cell cycle.
Human macrophages express a repertoire of TLRs with
functional responses to natural ligands or agonists. Nonetheless,
our studies indicated that TLR recognition of HIV-1 replicating in
macrophages is impaired, not only during initial infection, but
over the course of viral spread, ruling out the possibility that
infection of small numbers of cells limited detection of TLR
signaling. Manipulation of TLR signaling by a variety of
mechanisms is a survival technique evolved by a number of
viruses, including human cytomegalovirus, influenza virus, and
hepatitis C virus [22,62–64]. Cytosolic pattern recognition
receptors, RIG-I and MDA5, cross-talk through molecular hubs,
such as NF-kB and IRF-3, result in proinflammatory cytokine
responses similar to responses through TLRs. Our results indicate
that HIV-1 infection involves global evasion of molecular pattern
recognition receptors within macrophages. HIV-1 might passively
evade pattern recognition, actively inhibit or suppress recognition
and signaling, or require dynamic interactions between macro-
phages and other cells, such as lymphocytes or endothelial cells.
Immune activation and inflammatory responses correlate with
HIV-1 disease pathogenesis [65], and macrophages are central
regulators of systemic immune activation and targets of HIV-1
infection [40,66]. Macrophage activation is a multistep process
resulting in at least two major categories of activation, M1 or
classical activation and M2 or alternative activation [30]. Classical
macrophage activation involves two steps, priming and triggering,
which modulate gene or protein expression [31,32]. HIV-1 can
stimulate macrophages through a variety of signaling pathways,
including calcium, MAPK, and apoptosis, which are connected
with TLR through the NF-kB molecular hub. Nonetheless, HIV-1
fails to induce TLR-mediated activation indirectly through cross-
talk or as a direct trigger. The TLR signaling cascade, which can
be activated in pDC by HIV-1 RNA, failed to promote activation
in macrophages in response to HIV-1, indicating that viral evasion
of TLR may be a cell-type and/or virus-specific survival strategy.
Even though virus was inadequate to provide classical activation
of macrophages through TLR signaling, HIV-1 clearly primed
macrophages to be hypersensitive to TLR agonists. While the viral
doses applied to macrophages in our studies were insufficient to
result in detectable levels of TNF, IL-1b, or IL-6 secretion, cells
primed by HIV-1 produced enhanced cytokine levels following
TLR ligand treatment. HIV-1-induced priming of macrophages is
distinct from traditional IFN-c priming signals, based on STAT1
phosphorylation and multimerization as well as expression of
interferon-stimulated genes, in particular Mx1 [12,67,68]. The
Figure 7. TLR pathway is unaltered by HIV-1. TLR signaling pathway. Factors increased in expression by HIV-1 treatment are red and factors
expressed at lower levels by virus are green. Ovals represent factors detected at the RNA level. Signaling hubs are depicted with a yellow border.
doi:10.1371/journal.pone.0003664.g007
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designated M1HIV. TLR stimulation results in a state of tolerance,
due to degradation of activated signaling members within the TLR
pathway, such as IRAK1, which prevents cells from mounting a
response upon subsequent challenge. M1HIV-activated macro-
phages can undergo TLR tolerance upon stimulation with TLR
ligands, indicating viral proteins do not mimic TLR signaling.
Macrophage sensitization to microbial components may contrib-
ute to disease progression in HIV-1-positive individuals who have
compromised gut-associated lymphoid tissues and increased
microbial translocation into the plasma [69].
Several possible mechanisms may account for macrophage
sensitization to TLR ligands during HIV-1 infection. While
activation of pattern recognition receptors, such as TLRs, can
induce positive-feedback loops resulting in increased expression of
TLRs and proinflammatory cytokines, HIV may selectively
activate specific components of this response in macrophages
through signaling cross-talk, independent of TLR recognition,
resulting in increased TLR expression levels [70] in the absence of
proinflammatory cytokine production. For example, activity of
NF-kB during HIV infection may contribute to TLR-independent
enhanced responsiveness of macrophages. Consequently, novel
therapeutics might selectively suppress exaggerated innate im-
mune responses induced by HIV-1 infection, without inhibiting
protective TLR responses.
Macrophages regulate HIV-1 disease progression through their
secretory products [40,66]. HIV-1-induced macrophage sensitiza-
tion may correlate with poor clinical outcome if priming in vivo
increases disease sequelae by coinfecting pathogens. Viral tropism
Figure 8. HIV-1 fails to activate TLR in macrophages. Macrophages were treated with LPS (A–C), Poly(I:C) (D–F), or HIV-1 (G–I) for 24 hours.
Whole cell lysates from the indicated hours of treatment were western blotted for IRAK-1, p-IRF-3, IRF-3, and actin (A, D, and G). Relative abundance
levels of IRAK-1 (solid line, squares) and p-IRAK-1 (dotted line, squares) from western blot are displayed in line graphs (B, E, and H). IRF-3 (solid line,
triangles) and p-IRF-3 (dotted line, triangles) relative abundance levels are also represented in line plots (C, F, and I).
doi:10.1371/journal.pone.0003664.g008
Figure 9. Macrophages fail to produce Mx1 in response to HIV-
1. Whole cell lysates derived from macrophages treated with media,
HIV-1, LPS, Poly(I:C), or CL075 for 24 hours were immunoblotted for
Mx1 or actin protein expression.
doi:10.1371/journal.pone.0003664.g009
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raising the possibility that viruses may evolve in their potential to
prime macrophages concomitant with the evolution of coreceptor
use from CCR5 to CXCR4 [72,73] or increased tropism for
macrophages by CCR5-using viruses [74]. Macrophage priming
potential by quasispecies of HIV-1 may provide a novel biomarker
for assessing the course of HIV-1 disease progression within
infected individuals.
Materials and Methods
Preparation of viral stocks
A stock of macrophage-tropic, CCR5 using HIV-1JR-FL (NIH
Aids Reference and Reagent Program, Rockville, MD) was
prepared in peripheral blood mononuclear cells (PBMC), as
previously described [75]. A stock of macrophage-tropic CCR5
using HIV-1AD was prepared by transfection of the molecular
clone into 293T cells [76]. Viral stocks were titered on PBMCs as
previously described [75].
Viral treatment of macrophages
Monocytes from healthy human donors were differentiated into
macrophages over the course of 7 days in culture, and treated with
either HIV-1JR-FL (15,000 TCID50 per ml) or mock supernatants
for 24 hours as previously described [13]. Four independent
experiments using macrophages from different donors provided a
90% chance of detecting a two-fold difference between virus- and
mock-treated cultures, based on analysis of variance using a
randomized complete block design, a two-sided t-test, and a
standard deviation of 0.5.
Total RNA for each sample was extracted and prepared for
hybridization according to GeneChipH for use with HG-U95A
(version 2) arrays (Affymetrix, Santa Clara, CA). Specific
conditions were described previously [13]. High-resolution chip
images were analyzed using Microarray Suite Version 4
(Affymetrix). Signal intensity values from microarrays were
normalized and converted to fold-change values as previously
described [13]. GeneChip information was submitted to the Gene
Expression Omnibus at the NCBI (GEO: GSE13395).
RNA data analysis
A custom relational database was designed using Microsoft Access
2003H on the Windows XP ProH platform (Microsoft Corporation,
Redmond, WA). The database contains all raw data, as well as links
between unique gene identifiers for mRNA and protein, functional
categories, and summary of function. Functional categories of genes
were based on the Gene Ontology (GO) Consortium public domain
database (http://www.geneontology.org/). Cluster analysis was
performed to gain an overview of temporal gene expression patterns
within the dataset. Prior to clustering, filters were applied so that a
robust set of genes could be analyzed. Genes were first filtered to
remove any transcripts that were considered absent under all
conditions. A subsequent filter identified genes in infected cultures
that displayed greater than four-fold change (induced or repressed) in
hybridization intensities relative to levels in uninfected cultures.
Average linkage hierarchical agglomerative clustering with un-
centered correlation was performed on the median values obtained
for each probe set for all donors at each time point using the software
package Cluster (Mike Eisen, Berkeley, CA). Major branches in the
dendrogram were defined by correlation coefficients of greater than
0.75 (mean 0.85, range 0.75 to 0.96). Probe sets were classified as
altered in expression, expressed exclusively in HIV-1-treated, or
mock-treated macrophages, as previously described [13].
Intracellular protein determinations
Total proteins were extracted from macrophages from each of
four donors following treatment as previously described [13].
Macrophages from two of the four donors were assayed for both
proteins and mRNA. Immunoblot analysis of about 1000
intracellular proteins was performed by BD Biosciences (BD
Biosciences, Franklin Lakes, NJ). Approximately 860 proteins,
including 33 phosphorylated targets, were identified by an Entrez
Gene ID. The Affymetrix GeneChips contained probe sets that
matched 567 proteins assayed for in the PowerBlot. Proteins were
Figure 10. HIV-1 spread correlates with increased TLR response. Macrophages were treated with HIV-1 or media alone for 24 hours. Virus
was allowed to spread in culture for an additional 9 days. Viral replication in culture is represented by supernatant p24 levels (inset). Diamonds
represent untreated and squares represent HIV-1 treated. At the designated days of HIV-1 priming, cells were treated for 24 hours with LPS, Poly(I:C),
or CL075. Supernatants were collected and levels of TNF are represented in the bar graph.
doi:10.1371/journal.pone.0003664.g010
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expression differed $1.5 fold, corresponding to 305 proteins,
and 18 of these proteins were also altered at the gene level.
For immunoblot analysis of phosphoproteins in the TLR
pathway, countercurrent centrifugal elutriated monocytes were
kindly provided by Howard Gendelman and differentiated into
macrophages over 7 days at 37uC and 5% CO2 in the presence of
10% heat-inactivated pooled human serum, 1% glutamine,
10 mg/ml ciprofloxacin, and 1000 U/ml recombinant MCSF
[77]. Cells (3610
6 cells per well) were treated for indicated time
periods with 1 mg/ml E.coli 0111:B4 LPS (Sigma-Aldrich, St.
Louis, MO), 100 mg/ml Poly(I:C) (Invivogen, San Diego, CA), or
15,000 TCID50 HIV-1AD. Following treatment, macrophages
were washed twice with phosphate-buffered saline (PBS), pH 7.4,
and immediately lysed in ice-cold lysis buffer (1% Triton X-100,
2 mM Tris-HCl, 150 mM NaCl, 5 mM EDTA, 1 mM DTT,
1 mM NaF, 1mM Sodium Orthovanadate, 1 Protease Inhibitor
Cocktail Tablet (Roche, Basel, Switzerland), 1% Phosphatase
Inhibitor Cocktail I (Sigma-Aldrich), and 1% Phosphatase
Inhibitor Cocktail II (Sigma-Aldrich)). Whole-cell lysates were
centrifuged at 6,0006g for 10 min at 4uC, and the supernatants
were frozen at 280uC. The protein concentrations of cell extracts
were determined by the BCA protein assay (Bio-Rad, Hercules,
CA). Aliquots of cell extracts containing 15 mg of total proteins
were diluted in Laemlli Sample Buffer with 5% b- mercaptoeth-
anol, and resolved on 4–20% sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE) and transferred to a PVDF
membrane (Bio-Rad). Membranes were blocked with 5% milk in
TTBS (10 mM Tris, pH 7.4, 100 mM NaCl, 0.1% Tween 20) for
1 hour at room temperature and probed with mouse anti-IRAK-1
antibody (Santa Cruz Biotechnology, Santa Cruz, CA), rabbit
anti-pIRF-3 (Cell Signaling Technology, Danvers, MA), mouse
anti-IRF-3 (Santa Cruz Biotechnology), goat anti-Mx1 (Santa
Cruz Biotechnology), or mouse anti-b-actin (Santa Cruz Biotech-
nology), followed by goat anti-mouse IgG-HRP (Cell Signaling
Technology), mouse anti-goat IgG-HRP (Santa Cruz Biotechnol-
ogy), or goat anti-rabbit IgG-HRP (Cell Signaling Technology).
Horseradish peroxidase activity was visualized through enhanced
chemiluminescence detection Visualizer (Upstate, Charlottesville,
VA) for low abundant proteins, such as p-IRF-3, or Luminol
(Santa Cruz Biotechnology) followed by exposure to CL-Xposure
film (Thermo Scientific, Waltham, MA). Relative abundance of
bands was measured in Adoby Photoshop CS3 (San Jose, CA).
Density of individual bands were normalized to respective actin for
each lane.
Secreted cytokine determination
Elutriated monocytes from three independent donors were
plated at a density of 2.5610
5 cells per well in a 48 well plate, and
differentiated for 7 days into macrophages as previously described.
Macrophages were treated with either media or 5,000 TCID50
HIV-1AD (MOI=0.02) for 24 hours. Cells were washed with PBS
and incubated in media for 9 days with 50% media changes every
2 days. Macrophages were washed with PBS and treated for
24 hours with 1 mg/ml E.coli 0111:B4 LPS (Sigma-Aldrich),
100 mg/ml Poly(I:C) (Invivogen), 1 mg/ml CL097 (Invivogen),
1 mg/ml CL075 (Invivogen), 10 mg/ml R837 (Invivogen), 5,000
TCID50 HIV-1AD, or media. Supernatants were collected and
levels of TNF, IL-6, and IL-1b were quantified by ELISA (BD
Biosciences).
Proliferation assay
Freshly isolated PBMCs were purified and washed as previously
described [75]. Macrophages and PBMCs were treated at room
temperature for 8 minutes with 5 mM CFDA-SE (Invitrogen,
Carlsbad, CA). The reaction was immediately quenched with the
addition of PBS plus 10% FBS and cells were washed 5 times with
16PBS. Macrophages were incubated with either media or media
plus 50,000 TCID50 HIV-1AD (MOI=0.017) for 24 hours at
37uC. Macrophages were washed once with 16 PBS and
incubated in media for 9 days at 37uC with 50% media changes
every 2 days. After 10 days in culture with either media or virus,
macrophages were washed 4 times with 16 PBS and gently
scrapped. PBMCs were isolated and cultured as previously
described [78]. Cells were treated with media or 9 mg/ml PHA
(Sigma-Aldrich) for 4 days with 50% media changes every 2 days,
and washed 4 times with 16 PBS. Cells were pelleted through
centrifugation at 2506g for 10 minutes, resuspended in 1 ml 16
PBS, and fluorescent intensity was measured by flow cytometry in
a BD FACSCalibur (BD Biosciences).
Pathway analysis
Pathway-Express [43], was used to identify signaling pathways
in macrophages altered with statistical significance [P,0.05].
Signaling pathways were constructed from several sources,
including Kyoto Encyclopedia of Genes and Genomes (KEGG)
(Kanehisa Laboratory, Bioinformatics Center, Institute for Chem-
ical Research, Kyoto University), BioCarta, Inc. (San Diego, CA),
Protein Lounge (San Diego, CA), and literature searches. Lists of
genes and proteins whose relative expression level differences met
the criteria as altered by viral treatment were integrated and
displayed on constructed signaling pathways. Factors that
participate in more than one signaling pathway were considered
molecular hubs.
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Figure 11. HIV-1 priming enhances macrophage cytokine production in response to TLR stimulation. Macrophages were treated with
HIV-1 or media alone for 24 hours. Virus was allowed to spread in culture for an additional 9 days. Macrophages in the absence (gray bars) or
presence (black bars) of spreading virus were treated with media, HIV-1, LPS, Poly(I:C), CL097, CL075, or R837 for 24 hours, and supernatant TNF (A),
IL-6 (B), or IL-1b (C) levels were measured.
doi:10.1371/journal.pone.0003664.g011
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